Vanguard Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $382M | Sell |
4,761,135
-73,511
| -2% | -$4.94M | 0.01% | 1211 |
|
|
2025
Q3 | $236M | Sell |
4,834,646
-118,686
| -2% | -$7.35M | ﹤0.01% | 1462 |
|
|
2025
Q2 | $370M | Sell |
4,953,332
-146,289
| -3% | -$9.69M | 0.01% | 1202 |
|
|
2025
Q1 | $324M | Sell |
5,099,621
-79,767
| -2% | -$5.43M | 0.01% | 1234 |
|
|
2024
Q4 | $404M | Buy |
5,179,388
+10,119
| +0.2% | +$813K | 0.01% | 1168 |
|
|
2024
Q3 | $416M | Buy |
5,169,269
+28,567
| +0.6% | +$2.31M | 0.01% | 1144 |
|
|
2024
Q2 | $425M | Sell |
5,140,702
-256,628
| -5% | -$22.6M | 0.01% | 1071 |
|
|
2024
Q1 | $461M | Sell |
5,397,330
-8,979
| -0.2% | -$705K | 0.01% | 1043 |
|
|
2023
Q4 | $462M | Buy |
5,406,309
+25,451
| +0.5% | +$2.2M | 0.01% | 1015 |
|
|
2023
Q3 | $482M | Buy |
5,380,858
+27,146
| +0.5% | +$2.42M | 0.01% | 914 |
|
|
2023
Q2 | $456M | Buy |
5,353,712
+28,725
| +0.5% | +$2.43M | 0.01% | 979 |
|
|
2023
Q1 | $441M | Buy |
5,324,987
+82,151
| +2% | +$6.65M | 0.01% | 978 |
|
|
2022
Q4 | $412M | Buy |
5,242,836
+47,641
| +0.9% | +$3.83M | 0.01% | 989 |
|
|
2022
Q3 | $385M | Buy |
5,195,195
+173,113
| +3% | +$12.4M | 0.01% | 983 |
|
|
2022
Q2 | $327M | Buy |
5,022,082
+112,186
| +2% | +$6.64M | 0.01% | 1123 |
|
|
2022
Q1 | $310M | Buy |
4,909,896
+28,960
| +0.6% | +$1.57M | 0.01% | 1276 |
|
|
2021
Q4 | $259M | Sell |
4,880,936
-6,542
| -0.1% | -$399K | 0.01% | 1444 |
|
|
2021
Q3 | $345M | Sell |
4,887,478
-203
| -0% | -$12.8K | 0.01% | 1225 |
|
|
2021
Q2 | $326M | Buy |
4,887,681
+4,068
| +0.1% | +$288K | 0.01% | 1286 |
|
|
2021
Q1 | $542M | Buy |
4,883,613
+31,331
| +0.6% | +$3.88M | 0.01% | 908 |
|
|
2020
Q4 | $576M | Sell |
4,852,282
-12,552
| -0.3% | -$1.35M | 0.02% | 804 |
|
|
2020
Q3 | $424M | Sell |
4,864,834
-436,179
| -8% | -$38.1M | 0.01% | 844 |
|
|
2020
Q2 | $475M | Sell |
5,301,013
-222,475
| -4% | -$22.5M | 0.02% | 789 |
|
|
2020
Q1 | $550M | Buy |
5,523,488
+292,293
| +6% | +$31.7M | 0.02% | 641 |
|
|
2019
Q4 | $601M | Sell |
5,231,195
-17,397
| -0.3% | -$2.1M | 0.02% | 741 |
|
|
2019
Q3 | $662M | Sell |
5,248,592
-347,740
| -6% | -$44.1M | 0.02% | 667 |
|
|
2019
Q2 | $673M | Sell |
5,596,332
-39,200
| -0.7% | -$3.86M | 0.03% | 667 |
|
|
2019
Q1 | $493M | Buy |
5,635,532
+15,535
| +0.3% | +$1.41M | 0.02% | 791 |
|
|
2018
Q4 | $562M | Buy |
5,619,997
+290
| +0% | +$30.5K | 0.03% | 656 |
|
|
2018
Q3 | $644M | Buy |
5,619,707
+107,357
| +2% | +$11.1M | 0.03% | 672 |
|
|
2018
Q2 | $494M | Sell |
5,512,350
-134,810
| -2% | -$11.4M | 0.02% | 781 |
|
|
2018
Q1 | $413M | Buy |
5,647,160
+630,465
| +13% | +$43.3M | 0.02% | 844 |
|
|
2017
Q4 | $291M | Buy |
5,016,695
+131,433
| +3% | +$6.92M | 0.01% | 1038 |
|
|
2017
Q3 | $219M | Buy |
4,885,262
+142,218
| +3% | +$5.91M | 0.01% | 1212 |
|
|
2017
Q2 | $187M | Buy |
4,743,044
+48,719
| +1% | +$2M | 0.01% | 1271 |
|
|
2017
Q1 | $190M | Buy |
4,694,325
+332,087
| +8% | +$13M | 0.01% | 1254 |
|
|
2016
Q4 | $175M | Buy |
4,362,238
+167,795
| +4% | +$6.33M | 0.01% | 1260 |
|
|
2016
Q3 | $152M | Buy |
4,194,443
+157,352
| +4% | +$5.4M | 0.01% | 1289 |
|
|
2016
Q2 | $117M | Buy |
4,037,091
+70,299
| +2% | +$2.12M | 0.01% | 1411 |
|
|
2016
Q1 | $139M | Buy |
3,966,792
+129,864
| +3% | +$4.19M | 0.01% | 1245 |
|
|
2015
Q4 | $124M | Buy |
3,836,928
+64,249
| +2% | +$2.08M | 0.01% | 1316 |
|
|
2015
Q3 | $122M | Buy |
3,772,679
+12,531
| +0.3% | +$472K | 0.01% | 1301 |
|
|
2015
Q2 | $156M | Buy |
3,760,148
+110,618
| +3% | +$4.66M | 0.01% | 1231 |
|
|
2015
Q1 | $164M | Buy |
3,649,530
+169,798
| +5% | +$7.1M | 0.01% | 1152 |
|
|
2014
Q4 | $130M | Buy |
3,479,732
+17,823
| +0.5% | +$653K | 0.01% | 1236 |
|
|
2014
Q3 | $121M | Sell |
3,461,909
-3,745
| -0.1% | -$134K | 0.01% | 1225 |
|
|
2014
Q2 | $122M | Sell |
3,465,654
-72,763
| -2% | -$2.43M | 0.01% | 1258 |
|
|
2014
Q1 | $115M | Buy |
3,538,417
+138,833
| +4% | +$5.31M | 0.01% | 1264 |
|
|
2013
Q4 | $143M | Buy |
3,399,584
+208,295
| +7% | +$8.57M | 0.01% | 1084 |
|
|
2013
Q3 | $127M | Buy |
3,191,289
+95,587
| +3% | +$4.01M | 0.01% | 1088 |
|
|
2013
Q2 | $128M | Buy |
+3,095,702
| New | +$125M | 0.01% | 1005 |
|
Other funds holding HAE
Vanguard Group's HAE Position: Q4 2025 in Review
Vanguard Group reduced its Haemonetics (HAE) stake by 1.5% in Q4 2025, selling an estimated $4.94M and leaving 4,761,135 shares worth $382M. The position accounts for 0.01% of the portfolio, ranked #1211.
Vanguard Group first reported a position in HAE in Q2 2013 and has held it in 51 quarters since. The position peaked at $673M in Q2 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.
- Vanguard Group held 4,761,135 shares of Haemonetics worth $382M as of Q4 2025.
- Vanguard Group sold 73,511 Haemonetics shares in Q4 2025, an estimated $4.94M.
- Haemonetics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1211 holding.
- Vanguard Group first reported a position in Haemonetics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Haemonetics position peaked at $673M in Q2 2019.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.